Skip to main content

Table 1 Overall results from 3-months CDI surveillance in the Czech Republic; CDI Clostridium difficile infection, CI confidential interval

From: The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients

Clostridium (Clostridioides) difficile infections (CDI) by type, 16 hospitals, 10–12/2017 Number (%) Mean incidence density (95% CI)
CDI cases 433 (100) 4.5 [95% CI 3.6–5.2]
Healthcare-associated CDIs 330 (76.2) 3.5 [95% CI 2.8–4.1]
Community-associated and unknown origin CDIs 52 (12.0) 0.5 [95% CI 0.3–0.8]
Recurrent CDI 51 (11.8) 0.5 [95% CI 0.3–0.7]
Complicated course 65 (15.0)  
Death 88 (20.3)  
Characterisation of C. difficile isolates, 16 hospitals, 10–12/2017 379 (87.5)  
Ribotyping and toxin genes detection
Ribotype 001 127 (33.5)  
Ribotype 176 44 (11.6)  
Others (30 profiles) 208 (54.9)  
Binary toxin genes positive 75 (19.8)  
Antimicrobial susceptibility testing Susceptible (%) Reduced susceptibility (%)
Metronidazole (breakpoint 2 mg/L) 360 (95.0) n = 19 (5.0), RTs: 001 n = 8, 027 n = 6, 176 n = 5
Vancomycin (breakpoint 2 mg/L) 377 (99.5) n = 2 (0.5), RTs: 001, 012 n = 1, each
Moxifloxacin (breakpoint 4 mg/L) 193 (50.9) n = 186 (49.1), RTs: 001 n = 114, 002 n = 1, 012 n = 8, 017 n = 1, 027 n = 9,
033 n = 1, 078 n = 2, 126 n = 3, 176 n = 44, unrecognized n = 3